New drug cocktail aims to slash leukemia relapse after transplant
NCT ID NCT07101588
Summary
This study is testing if adding two drugs, ruxolitinib and decitabine, to the standard pre-transplant treatment can better prevent leukemia from coming back. It will involve 200 high-risk acute myeloid leukemia patients who are in their first remission and receiving a donor stem cell transplant. The goal is to see if this new combination is more effective and less toxic than the current standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.